KR101376449B1 - 피타바스타틴 및 에이코사펜타엔산 함유 고지혈증 치료제 - Google Patents

피타바스타틴 및 에이코사펜타엔산 함유 고지혈증 치료제 Download PDF

Info

Publication number
KR101376449B1
KR101376449B1 KR1020067016099A KR20067016099A KR101376449B1 KR 101376449 B1 KR101376449 B1 KR 101376449B1 KR 1020067016099 A KR1020067016099 A KR 1020067016099A KR 20067016099 A KR20067016099 A KR 20067016099A KR 101376449 B1 KR101376449 B1 KR 101376449B1
Authority
KR
South Korea
Prior art keywords
pitavastatin
eicosapentaenoic acid
hyperlipidemia
triglycerides
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067016099A
Other languages
English (en)
Korean (ko)
Other versions
KR20060109988A (ko
Inventor
다로 아오키
준지 야마구치
유스케 사사키
Original Assignee
닛산 가가쿠 고교 가부시키 가이샤
코와 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛산 가가쿠 고교 가부시키 가이샤, 코와 가부시키가이샤 filed Critical 닛산 가가쿠 고교 가부시키 가이샤
Publication of KR20060109988A publication Critical patent/KR20060109988A/ko
Application granted granted Critical
Publication of KR101376449B1 publication Critical patent/KR101376449B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067016099A 2004-02-19 2005-02-18 피타바스타틴 및 에이코사펜타엔산 함유 고지혈증 치료제 Expired - Fee Related KR101376449B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/780,640 2004-02-19
US10/780,640 US7022713B2 (en) 2004-02-19 2004-02-19 Hyperlipemia therapeutic agent
PCT/JP2005/003092 WO2005079797A2 (en) 2004-02-19 2005-02-18 Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid

Publications (2)

Publication Number Publication Date
KR20060109988A KR20060109988A (ko) 2006-10-23
KR101376449B1 true KR101376449B1 (ko) 2014-03-19

Family

ID=34860884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067016099A Expired - Fee Related KR101376449B1 (ko) 2004-02-19 2005-02-18 피타바스타틴 및 에이코사펜타엔산 함유 고지혈증 치료제

Country Status (14)

Country Link
US (2) US7022713B2 (https=)
EP (1) EP1715865B9 (https=)
JP (1) JP5474276B2 (https=)
KR (1) KR101376449B1 (https=)
CN (1) CN100475208C (https=)
AT (1) ATE460164T1 (https=)
CY (1) CY1110133T1 (https=)
DE (1) DE602005019856D1 (https=)
DK (1) DK1715865T3 (https=)
ES (1) ES2342609T3 (https=)
PL (1) PL1715865T3 (https=)
PT (1) PT1715865E (https=)
SI (1) SI1715865T1 (https=)
WO (1) WO2005079797A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091660A1 (ja) * 2003-04-17 2004-10-28 Kowa Co., Ltd. Lklf/klf2遺伝子発現促進剤
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1982710B1 (en) * 2006-02-07 2013-12-18 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
JP5069448B2 (ja) * 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US7728697B2 (en) * 2006-09-26 2010-06-01 Mg Materials Corporation Systems and methods for electrically reducing ferroelectric materials to increase bulk conductivity
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
WO2010004982A1 (ja) * 2008-07-07 2010-01-14 持田製薬株式会社 脂質異常症の改善または治療薬
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9717703B2 (en) * 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) * 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2926335C (en) 2013-10-30 2021-11-23 Banner Life Sciences Llc Enteric soft capsules comprising polyunsaturated fatty acids
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
CN107427489A (zh) * 2014-08-22 2017-12-01 财团法人教育研究基金会 用于治疗非酒精性脂肪肝疾病的药物及应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114685A1 (en) * 2001-08-16 2003-06-19 Valerie Niddam-Hildesheim Processes for preparing calcium salt forms of statins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
CN1109543C (zh) * 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1370544A (zh) * 2001-02-27 2002-09-25 张洪超 一种具有降血脂作用的林蛙卵油营养保健胶囊及其制法
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
CN1197564C (zh) * 2001-09-30 2005-04-20 中国药品生物制品检定所 海狗油在制备治疗脂代谢紊乱药物中的应用
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114685A1 (en) * 2001-08-16 2003-06-19 Valerie Niddam-Hildesheim Processes for preparing calcium salt forms of statins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Life Sciences 61(20): 2007-2015 (1997) *
Life Sciences 61(20): 2007-2015 (1997)*

Also Published As

Publication number Publication date
HK1098953A1 (zh) 2007-08-03
WO2005079797A2 (en) 2005-09-01
ATE460164T1 (de) 2010-03-15
DE602005019856D1 (de) 2010-04-22
EP1715865A2 (en) 2006-11-02
WO2005079797A3 (en) 2006-05-11
CY1110133T1 (el) 2015-01-14
PL1715865T3 (pl) 2010-09-30
CN100475208C (zh) 2009-04-08
EP1715865B8 (en) 2010-05-19
EP1715865B1 (en) 2010-03-10
US20060111437A1 (en) 2006-05-25
KR20060109988A (ko) 2006-10-23
CN1921860A (zh) 2007-02-28
EP1715865B9 (en) 2010-12-15
DK1715865T3 (da) 2010-05-10
US20050187292A1 (en) 2005-08-25
US7022713B2 (en) 2006-04-04
ES2342609T3 (es) 2010-07-09
SI1715865T1 (sl) 2010-08-31
US7776881B2 (en) 2010-08-17
JP5474276B2 (ja) 2014-04-16
PT1715865E (pt) 2010-04-01
JP2007523049A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
KR101376449B1 (ko) 피타바스타틴 및 에이코사펜타엔산 함유 고지혈증 치료제
DK169593B1 (da) Farmaceutiske præparater med forbedret stabilitet samt fremgangsmåde til stabilisering af et ACE-inhibitor lægemiddel
EP2007429B1 (en) Oral formulation with beneficial cardiovascular effects, comprising berberine
KR101420319B1 (ko) 고지혈증 예방 및/또는 치료제
RS51449B (sr) Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
CZ17699A3 (cs) Antithrombosová a antiatherogenní farmaceutická kompozice, obsahující derivát thienopyridinu a inhibitor HMG-CoA-reduktasy
KR20070047766A (ko) 고지혈증 치료제
EP0373507A1 (en) Combination of an HMG CoA reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
KR100742432B1 (ko) 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100846641B1 (ko) 동맥경화 억제 방법 및 조성물
KR101258422B1 (ko) 신규의 트리글리세리드 저하제
CN101242828B (zh) 抑制酰基辅酶a：胆固醇酰基转移酶的组合物
CN106937952A (zh) 依折麦布和辛伐他汀的制剂
US20040023919A1 (en) Blood lipid ameliorant composition
HK1098953B (en) Hyperlipemia therapeutic agent
US20090318496A1 (en) Preparation containing fibrate agent and process for producing the same
JP2005089300A (ja) 高脂血症治療剤
HK1132908A (en) Drug formulation containing fibrate medicament and process for producing the same
WO1993009773A1 (fr) Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee
MX2009001218A (es) Preparacion que contiene un agente de fibrato y un proceso para producir el mismo.
KR20130123564A (ko) 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 경구투여용 약학 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120727

Effective date: 20130523

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20130523

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2006 7016099

Appeal request date: 20120727

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2012101006960

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170307

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190314

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190314

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000